SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001140361-17-045018
Filing Date
2017-12-05
Accepted
2017-12-05 12:56:27
Documents
1
Period of Report
2017-12-01

Document Format Files

Seq Description Document Type Size
1 FORM 4 doc1.html 4  
1 FORM 4 doc1.xml 4 4964
  Complete submission text file 0001140361-17-045018.txt   6363
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Issuer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD, SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address
RAY DEBANJAN (Reporting) CIK: 0001706863 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37587 | Film No.: 171239177